Document:

EX-10.2

 

EXHIBIT 10.2

NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933 AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE
SECURITIES LAWS, AND, ACCORDINGLY MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR TRANSFERRED
EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN
AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL
OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY
ACCEPTABLE TO THE COMPANY.

COMMON STOCK WARRANT

To Purchase Shares of Common Stock of

EpiCept Corporation

Dated as of August 30, 2006 (the “Effective Date”)

     WHEREAS, EpiCept Corporation, a Delaware corporation (the “Company”), has entered into a Loan and
Security Agreement of even date herewith (the “Loan Agreement”) with Hercules Technology Growth
Capital, Inc., a Maryland corporation (the “Warrantholder”);

     WHEREAS, the Company desires to grant to Warrantholder, in consideration for, among other things,
the financial accommodations provided for in the Loan Agreement, the right to purchase shares of
its Common Stock, par value $0.0001 (the “Common Stock”), pursuant to this Warrant Agreement (the
“Agreement”);

     NOW, THEREFORE, the Company and Warrantholder agree as follows:

1. GRANT OF THE RIGHT TO PURCHASE COMMON STOCK.

     This Common Stock Warrant (the “Warrant”) certifies that for value received, the Company hereby
grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject to the
limitations on exercise and the conditions hereinafter set forth, at any time on or after the date
hereof and prior to the Termination Date (as defined below) to subscribe for and purchase, from the
Company, a number of fully paid and non-assessable shares of Common Stock equal to the quotient
derived by dividing (a) $1,250,000 by (b) the Exercise Price (the “Warrant Shares”). The exercise
price (the “Exercise Price”) will be equal to $2.65. If the Company receives proceeds on or before
the first anniversary of the Effective Date from the sale or issuance of its equity securities
(other than pursuant to options, warrants or securities outstanding on the Effective Date or
options or restricted stock issued pursuant to its equity compensation plans in effect on the
Effective Date) at a price per share of Common Stock (determined on an as exercised or as converted
basis, if applicable) that is lower than the Exercise Price, then in such event, the Exercise Price
shall be reduced, concurrently with such issue, to a price (calculated to the nearest cent)
determined by multiplying such Exercise Price by a fraction, (A) the numerator of which shall be
the number of shares of Common Stock outstanding immediately prior to such issue plus the number of
shares of Common Stock issuable upon exercise of this Warrant (using the

 1.

 

then-existing Exercise
Price) and (B) the denominator of which shall be the number of shares of Common Stock outstanding
immediately prior to such issue plus the number of shares of Common Stock so issued; provided that
in no
event shall the Exercise Price be reduced to a price below $0.01 per Share by operation of this
sentence. As used herein, the following terms shall have the following meanings:

          “Act” means the Securities Exchange Act of 1933, as amended.

          “Charter” means the Company’s Amended and Restated Certificate of Incorporation, as it may be
further amended from time to time.

          “Merger Event” means a merger or consolidation involving the Company in which the Company is
not the surviving entity, or in which the outstanding shares of the Company’s capital stock are
otherwise converted into or exchanged for shares of capital stock of another entity.

          “Purchase Price” means, with respect to any exercise of this Warrant, an amount equal to the
Exercise Price as of the relevant time multiplied by the number of shares of Common Stock requested
to be exercised under this Warrant pursuant to such exercise.

2. TERM.

     Except as otherwise provided for herein, the term of this Warrant and the right to purchase Common
Stock as granted herein shall commence on the Effective Date and shall be exercisable for a period
ending upon the fifth anniversary of the Effective Date (the “Termination Date”).

3. EXERCISE.

     (a) Exercise. The purchase rights set forth in this Warrant are exercisable by the Warrantholder,
in whole or in part, at any time, or from time to time, prior to the Termination Date set forth in
Section 2, by tendering to the Company at its principal office a notice of exercise in the form
attached hereto as Exhibit I (the “Notice of Exercise”), duly completed and executed. Promptly
upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the
terms set forth below, and as soon as practicable thereafter, the Company shall issue to the
Warrantholder a certificate for the number of shares of Common Stock purchased and shall execute
the acknowledgment of exercise in the form attached hereto as Exhibit II (the “Acknowledgment of
Exercise”) indicating the number of shares of Common Stock which remain subject to future
purchases, if any.

     The Purchase Price may be paid at the Warrantholder’s election either (i) by cash or check, or (ii)
by surrender of all or a portion of the Warrant for shares of Common Stock to be exercised under
this Warrant and, if applicable, an amended Warrant representing the remaining number of shares
purchasable hereunder, as determined below (“Net Issuance Method”). If the Warrantholder elects
the Net Issuance Method, the Company will issue Common Stock in accordance with the following
formula:

	 	 	 	 	 	 	 	 	 
	 

	 	X
	 	=
	 	Y(A-B)	 	 
	 

	 	 	 	 	 	A	 	 

	 	 	 	 	 	 	 
	Where:

	 	X
	 	=
	 	the number of shares of Common Stock to be issued to the Warrantholder.
	 
	 	 	 	 	 	 
	 

	 	Y
	 	=
	 	the number of shares of Common Stock requested to be
exercised under this Warrant.

 2.

 

	 	 	 	 	 	 	 
	 

	 	A
	 	=
	 	the fair market value of one (1) share of Common Stock on the
date the Common Stock is issued.
	 
	 	 	 	 	 	 
	 

	 	B
	 	=
	 	the Exercise Price, as adjusted.

          For purposes of the above calculation, current fair market value of Common Stock shall mean
with respect to each share of Common Stock:

          (i) if the Common Stock is listed on a securities exchange, and:

               (1) if the Common Stock is traded on a securities exchange, the fair market value shall be
deemed to be the average of the closing prices over a ten (10) day period ending three days before
the day the current fair market value of the Common Stock is being determined; or

               (2) if the Common Stock is actively traded over-the-counter, the fair market value shall be
deemed to be the average of the closing bid and asked prices quoted on the OTC Bulletin Board over
the ten (10) day period ending three days before the day the current fair market value of the
Common Stock is being determined; and

               (3) if at any time the Common Stock is not listed on any securities exchange or the
over-the-counter market, the current fair market value of Common Stock shall be the highest price
per share which the Company could obtain from a willing buyer (not a current employee or director)
for shares of Common Stock sold by the Company, from authorized but unissued shares, as most
recently determined in good faith by its Board of Directors, unless the Company shall become
subject to a Merger Event pursuant to which the Company is not the surviving party, in which case
the fair market value of Common Stock shall be deemed to be the per share value received by the
holders of the Company’s Common Stock on a common equivalent basis pursuant to such Merger Event.

     Upon partial exercise by either cash or Net Issuance Method, the Company shall promptly issue an
amended Warrant representing the remaining number of shares purchasable hereunder. All other terms
and conditions of such amended Warrant shall be identical to those contained herein, including, but
not limited to the Effective Date hereof.

     (b) Exercise Prior to Expiration. To the extent this Warrant is not previously exercised as to all
Common Stock subject hereto, and if the fair market value of one share of the Common Stock is
greater than the Exercise Price then in effect, this Warrant shall be deemed automatically
exercised pursuant to Section 3(a) (even if not surrendered) on the Termination Date. For purposes
of such automatic exercise, the fair market value of one share of the Common Stock on the
Termination Date shall be determined pursuant to Section 3(a). To the extent this Warrant or any
portion thereof is deemed automatically exercised pursuant to this Section 3(b), the Company agrees
to promptly notify the Warrantholder of the number of shares of Common Stock, if any, the
Warrantholder is to receive by reason of such automatic exercise.

4. RESERVATION OF SHARES.

     During the term of this Warrant, the Company will at all times have authorized and reserved a
sufficient number of shares of its Common Stock to provide for the exercise of the rights to
purchase Common Stock as provided for herein.

 3.

 

5. NO FRACTIONAL SHARES OR SCRIP.

     No fractional shares or scrip representing fractional shares shall be issued upon the exercise of
this Warrant, but in lieu of such fractional shares the Company shall, at its election, either pay
a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.

6. REGISTRATION RIGHTS. The Company shall file a registration statement with the SEC registering
the Common Stock issuable upon exercise of this Warrant no later than November 30, 2006 and shall
use its best efforts to cause such registration statement to remain effective through the
Termination Date.

7. WARRANTHOLDER REGISTRY.

     The Company shall maintain a registry showing the name and address of the registered holder of this
Warrant. The Warrantholder’s initial address, for purposes of such registry, is set forth
below Warrantholder’s signature on this Warrant. The Warrantholder may change such address by
giving written notice of such changed address to the Company.

8. ADJUSTMENT RIGHTS.

     The Exercise Price and the number of shares of Common Stock purchasable hereunder are subject to
adjustment, as follows:

     (a) Merger Event. If at any time there shall be Merger Event, then, as a part of such Merger Event,
lawful provision shall be made so that the Warrantholder shall thereafter be entitled to receive,
upon exercise of this Warrant, the number of shares of Common Stock or other securities or property
of the successor corporation resulting from such Merger Event that would have been issuable if the
Warrantholder had exercised this Warrant immediately prior to the Merger Event. In any such case,
appropriate adjustment (as determined in good faith by the Company’s Board of Directors) shall be
made in the application of the provisions of this Warrant with respect to the rights and interests
of the Warrantholder after the Merger Event such that the provisions of this Warrant (including
adjustments of the Exercise Price and number of shares of Common Stock issuable hereunder) shall be
applicable in their entirety, and to the greatest extent possible. Without limiting the foregoing,
in connection with any Merger Event, upon the closing thereof, the successor or surviving entity
shall assume the obligations of this Warrant.

     (b) Reclassification of Shares. Except as set forth in Section 8(a), if the Company at any time
shall, by combination, reclassification, exchange or subdivision of securities or otherwise, change
any of the securities as to which purchase rights under this Warrant exist into the same or a
different number of securities of any other class or classes, this Warrant shall thereafter
represent the right to acquire such number and kind of securities as would have been issuable as
the result of such change with respect to the securities which were subject to the purchase rights
under this Warrant immediately prior to such combination, reclassification, exchange, subdivision
or other change.

     (c) Subdivision or Combination of Shares. If the Company at any time shall combine or subdivide its
Common Stock, (i) in the case of a subdivision, the Exercise Price shall be proportionately
decreased, and the number of shares of Common Stock issuable upon exercise of this Warrant shall be
proportionately increased, or (ii) in the case of a combination, the Exercise Price shall be
proportionately increased, and the number of shares of Common Stock issuable upon the exercise of
this Warrant shall be proportionately decreased.

 4.

 

     (d) Stock Dividends. If the Company at any time while this Warrant is outstanding shall:

          (i) pay a dividend with respect to the Common Stock payable in Common Stock, then the Exercise
Price in effect immediately prior to the date of determination of stockholders entitled to receive
such dividend or distribution shall be multiplied by a fraction (A) the numerator of which shall be
the total number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately prior to such dividend or distribution, and (B) the denominator of which shall be the
total number of shares of Common Stock outstanding immediately after such dividend or distribution
and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
(any such adjustment made pursuant to this Section 8(d)(i) shall become effective immediately after
the record date for the determination of stockholders entitled to receive such dividend or
distribution); or

          (ii) make any other distribution with respect to Common Stock (or stock into which the Common
Stock is convertible), except any distribution specifically provided for in any other clause of
this Section 8, then, in each such case, provision shall be made by the Company such that the
Warrantholder shall receive upon exercise or conversion of this Warrant a proportionate share of
any such distribution as though it were the holder of the Common Stock (or other stock for which
the Common Stock is convertible) as of the record date fixed for the determination of the
shareholders of the Company entitled to receive such distribution.

     (e) Notice of Adjustments. Whenever an adjustment to the Exercise Price or the number of shares of
Common Stock issuable upon exercise of this Warrant is made pursuant to this Section 8, the Company
shall send to the Warrantholder a notice setting forth, in reasonable detail, (i) the event
requiring the adjustment, (ii) the amount of such adjustment, (iii) the method by which such
adjustment was calculated, (iv) the adjusted Exercise Price (if the Exercise Price has been
adjusted), and (v) the number of shares of Common Stock subject to purchase hereunder after giving
effect to such adjustment, and shall cause such notice to be mailed (by first class mail, postage
prepaid, or by reputable overnight courier with all charges prepaid) within thirty (30) days of
such adjustment addressed to the Warrantholder at the address for the Warrantholder set forth in
the registry referred to in Section 7.

9. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY.

     (a) Reservation of Common Stock. The Common Stock has been duly and validly reserved and, when
issued in accordance with the provisions of this Warrant, will be validly issued, fully paid and
non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature
whatsoever. The Company has made available to the Warrantholder true, correct and complete copies
of its Charter and Bylaws. The issuance of certificates for shares of Common Stock upon exercise
of this Warrant shall be made without charge to the Warrantholder for any issuance tax in respect
thereof, or other cost incurred by the Company in connection with such exercise and the related
issuance of shares of Common Stock; provided that the Company shall not be required to pay any tax
which may be payable in respect of any transfer and the issuance and delivery of any certificate in
a name other than that of the Warrantholder.

     (b) Due Authority. The execution and delivery by the Company of this Warrant and the performance of
all obligations of the Company hereunder, including the issuance to the Warrantholder of the right
to acquire the shares of Common Stock, have been duly authorized by all necessary corporate action
on the part of the Company. This Warrant: (1) is not inconsistent with the Company’s Charter or
Bylaws; (2) does not contravene any law or governmental rule, regulation or order applicable to it;
and (3) does not and will not contravene any provision of, or constitute a default under, any
indenture, mortgage, contract or other instrument to which it is a party or by which it is bound.
This Warrant constitutes a legal, valid and binding agreement of the Company, enforceable against
it in accordance with its terms.

 5.

 

     (c) Consents and Approvals. No consent or approval of, giving of notice to, registration with, or
taking of any other action in respect of any state, federal or other governmental authority or
agency is required with respect to the execution, delivery and performance by the Company of its
obligations under this Warrant, except for the filing of notices pursuant to Regulation D under the
Act and any filing required by applicable state securities law, which filings will be effective by
the time required thereby. All issued and outstanding shares of Common Stock have been duly
authorized and validly issued and are fully paid and nonassessable. All outstanding shares of
Common Stock were issued in full compliance with all federal and state securities laws. Attached
to this Warrant as Exhibit IV is a true and correct capitalization table of the Company.

     (d) Other Commitments to Register Securities. Except as set forth on Exhibit V, the Company is not,
pursuant to the terms of any other agreement currently in existence, under any obligation to
register under the Act any of its presently outstanding securities or any of its securities which
may hereafter be issued.

     (e) Exempt Transaction. Subject to the accuracy of the Warrantholder’s representations in Section
10, the issuance of the Common Stock upon exercise of this Warrant, will each constitute a
transaction exempt from (i) the registration requirements of Section 5 of the Act, in reliance upon
Section 4(2) thereof, and (ii) the qualification requirements of the applicable state securities
laws.

     (f) Compliance with Rule 144. If the Warrantholder proposes to sell Common Stock issuable upon the
exercise of this Warrant in compliance with Rule 144 promulgated by the Securities
and Exchange Commission (the “SEC”), then, upon the Warrantholder’s written request to the Company,
the Company shall furnish to the Warrantholder, within ten days after receipt of such request, a
written statement confirming, if true, the Company’s compliance with the filing requirements of the
SEC as set forth in such Rule, as such Rule may be amended from time to time if applicable to the
Company.

10. REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER.

     This Warrant has been entered into by the Company in reliance upon the following representations
and covenants of the Warrantholder:

     (a) Investment Purpose. This Warrant and the Common Stock that the Warrantholder will acquire upon
exercise of the Warrantholder’s rights contained herein will be acquired for its own account for
investment and not with a view to the sale or distribution of any part thereof, and the
Warrantholder has no present intention of selling or engaging in any public distribution of the
same except pursuant to an effective registration statement or an exemption from the Act.

     (b) Private Issue. The Warrantholder understands (i) neither this Warrant nor the Common Stock
issuable upon exercise of this Warrant is registered under the Act or qualified under applicable
state securities laws on the ground that the issuance contemplated by this Warrant will be exempt
from the registration and qualifications requirements thereof, and (ii) that the Company’s reliance
on such exemption is predicated on the representations set forth in this Section 10.

     (c) Disposition of the Warrantholder’s Rights. In no event will the Warrantholder make a
disposition of any of its rights to acquire Common Stock hereunder unless and until (i) it shall
have notified the Company of the proposed disposition, and (ii) if requested by the Company, it
shall have furnished the Company with an opinion of counsel (which counsel may either be inside or
outside counsel to the Warrantholder) reasonably satisfactory to the Company and its counsel to the
effect that (A) appropriate action necessary for compliance with the Act has been taken, or (B) an
exemption from the registration requirements of the Act is available. Notwithstanding the
foregoing, the restrictions

 6.

 

imposed upon the transferability of any of the Warrantholder’s rights
to acquire Common Stock hereunder do not apply to transfers from the beneficial owner of any of the
aforementioned securities to its nominee or from such nominee to its beneficial owner, or to any
transfers to an Affiliate of the Warrantholder, and shall terminate as to any particular share of
Common Stock when (1) such security shall have been effectively registered under the Act and sold
by the holder thereof in accordance with such registration or (2) such security shall have been
sold without registration in compliance with Rule 144 under the Act, or (3) a letter shall have
been issued to the Warrantholder at its request by the Staff of the SEC or a ruling shall have been
issued to the Warrantholder at its request by the SEC stating that no action shall be recommended
by such staff or taken by the SEC, as the case may be, if such security is transferred without
registration under the Act in accordance with the conditions set forth in such letter or ruling and
such letter or ruling specifies that no subsequent restrictions on transfer are required. Whenever
the restrictions imposed hereunder shall terminate, as hereinabove provided, the Warrantholder or
holder of a share of Common Stock then outstanding as to which such restrictions have terminated
shall be entitled to receive from the Company, without expense to such holder, one or more new
certificates for this Warrant or for such shares of Common Stock not bearing any restrictive
legend.

     (d) Financial Risk. The Warrantholder has such knowledge and experience in financial and business
matters as to be capable of evaluating the merits and risks of its investment, and has the ability
to bear the economic risks of its investment.

     (e) Accredited Investor. The Warrantholder is an “accredited investor” within the meaning of the
Rule 501 of Regulation D under the Act, as presently in effect.

11. TRANSFERS.

     Subject to compliance with any applicable securities laws and the terms and conditions contained in
Section 10, this Warrant and all rights hereunder (including, without limitation, any registration
rights) are transferable in whole or in part by the Warrantholder and any successor transferee upon
surrender of this Warrant at the principal office of the Company, together with a notice of
transfer in the form attached hereto as Exhibit III (the “Transfer Notice”), duly executed by the
Warrantholder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon
the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees and in the
denomination or denominations specified in such Transfer Notice, and shall issue to the assignor a
new Warrant evidencing the portion of the Warrant not so assigned, and this Warrant shall promptly
be cancelled. A Warrant, if properly assigned, may be exercised by a new holder for Warrant Shares
without having a new Warrant issued.

12. MISCELLANEOUS.

     (a) Effective Date. The provisions of this Warrant shall be construed and shall be given effect in
all respects as if it had been executed and delivered by the Company on the date hereof. This
Warrant shall be binding upon any successors or assigns of the Company.

     (b) Remedies. In the event of any default hereunder, the non-defaulting party may proceed to
protect and enforce its rights either by suit in equity and/or by action at law, including but not
limited to an action for damages as a result of any such default, and/or an action for specific
performance for any default where Warrantholder will not have an adequate remedy at law and where
damages will not be readily ascertainable.

     (c) No Impairment of Rights. The Company will not, by amendment of its Charter or through any other
means, avoid or seek to avoid the observance or performance of any of the terms of this

 7.

 

Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking
of all such actions as may be necessary or appropriate in order to protect the rights of the
Warrantholder against impairment.

     (d) Entire Agreement; Amendments. This Warrant constitutes the entire agreement and understanding
of the parties hereto in respect of the subject matter hereof, and supersedes and replaces in their
entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements,
whether written or oral, with respect to the subject matter hereof. None of the terms of this
Warrant may be amended except by an instrument executed by each of the parties hereto.

     (e) No Waiver. No omission or delay by the Warrantholder at any time to enforce any right or remedy
reserved to it, or to require performance of any of the terms, covenants or provisions hereof by
the Company at any time designated, shall be a waiver of any such right or remedy to which the
Warrantholder is entitled, nor shall it in any way affect the right of the Warrantholder to enforce
such provisions thereafter.

     (f) Survival. All agreements, representations and warranties contained in this Warrant or in any
document delivered pursuant hereto shall be for the benefit of the Warrantholder and shall survive
the execution and delivery of this Warrant and the expiration or other termination of this Warrant.

     (g) Governing Law. This Warrant shall be governed by, and construed and enforced in accordance
with, the laws of the State of Delaware, excluding conflict of laws principles that would cause the
application of laws of any other jurisdiction.

     (h) Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to
this Warrant may be brought in any state or federal court of competent jurisdiction located in the
State of California. By execution and delivery of this Warrant, each party hereto generally and
unconditionally: (a) consents to personal jurisdiction in Santa Clara County, California; (b)
waives any objection as to jurisdiction or venue in Santa Clara County, California; (c) agrees not
to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d)
irrevocably agrees to be bound by any judgment rendered thereby in connection with this Warrant.
Nothing herein shall affect the right to serve process in any other manner permitted by law or
shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.

     (i) Mutual Waiver of Jury Trial. Because disputes arising in connection with complex financial
transactions are most quickly and economically resolved by an experienced and expert person and the
parties wish applicable state and federal laws to apply (rather than arbitration rules), the
parties desire that their disputes arising out of this Warrant be resolved by a judge applying such
applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE
TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY
OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE
OR BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY IN CONNECTION WITH THIS WARRANT. If this
jury waiver is for any reason unenforceable, all disputes shall be resolved by judicial reference
under California Code of Civil Procedure Section 638.

     (j) Specific Performance. The Warrantholder and the Company agree that either may be irreparably
damaged by any breach or threatened breach of this Warrant. Upon a breach or threatened breach of
the terms, covenants and/or conditions of this Warrant by the Warrantholder or the Company, the
other party shall, in addition to all other remedies, be entitled to seek a temporary or permanent
injunction and/or a decree for specific performance, in accordance with the provisions hereof. The

 8.

 

Warrantholder and the Company each waives the claim or defense that it has an adequate remedy at
law, and such person shall not offer in any such action or proceeding the claim or defense that
such remedy at law exists.

     (k) No Shareholder Rights. This Warrant does not entitle the Warrantholder to any voting rights or
other rights as a shareholder of the Company prior to the exercise of this Warrant.

     (l) Saturdays, Sundays, Holidays Etc. If the last or appointed day for the taking of any action or
the expiration of any right required or granted herein shall not be a Business Day, then such
action may be taken or such right may be exercised on the next succeeding Business Day. “Business
Day” shall mean any day except Saturday, Sunday, any day which shall be a federal legal holiday in
the United States or any day on which banking institutions in the State of New York are authorized
or required by law or other governmental action to close.

     (m) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon
receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or
mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of
loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the
case of the Warrant, shall not include the posting of any bond), and upon surrender and
cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver
a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such
Warrant or stock certificate.

     (n) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any
right hereunder on the part of the Warrantholder shall operate as a waiver of such right or
otherwise prejudice Warrantholder’s rights, powers or remedies, notwithstanding the fact that all
rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails
to comply with any provision of this Warrant, which results in any material damages to the
Warrantholder, the Company shall pay to Warrantholder such amounts as shall be sufficient to cover
any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those
of appellate proceedings, incurred by Warrantholder in collecting any amounts due pursuant hereto
or in otherwise enforcing any of its rights, powers or remedies hereunder.

     (o) Counterparts. This Warrant and any amendments, waivers, consents or supplements hereto may be
executed in any number of counterparts, and by different parties hereto in separate counterparts,
each of which when so delivered shall be deemed an original, but all of which counterparts shall
constitute but one and the same instrument.

[Remainder of Page Intentionally Left Blank]

 9.

 

     IN WITNESS WHEREOF, the parties hereto have caused this Warrant to be executed by its officers
thereunto duly authorized as of the Effective Date.

	 	 	 	 	 	 	 
	COMPANY:	 	EpiCept Corporation	 	 
	 
	 	 	 	 	 	 
	 

	 	By: 	 	/s/ Robert W. Cook	 	 
	 

	 	 	 	 

	 	 
	 

	 	Title:	 	SVP & CFO	 	 
	 

	 	 	 	 

	 	 
	 	 	Attn:	 	 
	 	 	270 Sylvan Avenue	 	 
	 	 	Englewood Cliffs, NJ 07632	 	 
	 
	 	 	 	 	 	 
	WARRANTHOLDER:	 	Hercules Technology Growth Capital, Inc.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Scott Harney	 	 
	 

	 	 	 	 

	 	 
	 

	 	Title:	 	Chief Legal Officer 	 	 
	 

	 	 	 	 

	 	 
	 	 	Hercules Technology
Growth Capital, Inc..	 	 
	 	 	Attn: Chief Legal Officer	 	 
	 	 	525 University Avenue	 	 
	 	 	Suite 700	 	 
	 	 	Palo Alto, CA 94301	 	 

 10.

 

EXHIBIT I

NOTICE OF EXERCISE

To: EpiCept Corporation:

	(1)	 	The undersigned Warrantholder hereby elects to purchase [                    ] shares of the Common Stock
of EpiCept Corporation, pursuant to the terms of the Warrant dated August 28, 2006 (the
“Warrant”) between EpiCept Corporation and the Warrantholder, and [CASH PAYMENT: tenders
herewith payment of the Purchase Price in full, together with all applicable transfer taxes,
if any.] [NET ISSUANCE METHOD: elects pursuant to Section 3(a) of the Agreement to effect a
Net Issuance.]
	 
	(2)	 	In exercising its rights to purchase the Common Stock of EpiCept Corporation, the undersigned
hereby confirms and acknowledges the investment representations and warranties made in Section
10 of the Warrant.
	 
	(3)	 	Please issue a certificate or certificates representing said shares of Common Stock in the
name of the undersigned or in such other name as is specified below.

	 	 	 	 	 	 	 
	 	 	 	 	 
	 	 	(Name)	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 

	 	(Address)	 	 	 	 
	 
	 	 	 	 	 	 
	WARRANTHOLDER:	 	Hercules Technology Growth Capital, Inc.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 

	 	 
	 

	 	Title:	 	 	 	 
	 

	 	 	 	 

	 	 
	 

	 	Date:	 	 	 	 
	 

	 	 	 	 

	 	 

 11.

 

EXHIBIT II

ACKNOWLEDGMENT OF EXERCISE

The undersigned EpiCept Corporation, hereby acknowledge receipt of the “Notice of Exercise” from
Hercules Technology Growth Capital, Inc., to purchase [___] shares of the Common Stock of EpiCept
Corporation, pursuant to the terms of the Warrant, and further acknowledges that [                    ] shares
remain subject to purchase under the terms of the Warrant.

	 	 	 	 	 	 	 
	COMPANY:	 	EpiCept Corporation	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 

	 	 
	 

	 	Title:	 	 	 	 
	 

	 	 	 	 

	 	 
	 

	 	Date:	 	 	 	 
	 

	 	 	 	 

	 	 

 12.

 

EXHIBIT III

TRANSFER NOTICE

(To transfer or assign the foregoing Warrant execute this form and supply required information. Do
not use this form to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby transferred
and assigned to

	 	 	 	 	 
	 	 	 
	(Please Print)
	 	 	 	 
	 
	 	 	 	 
	whose address is

	 	 

	 	 
	 
	 	 

	 	 
	 
	 	 	 	 
	 	 	 

	 	 	 	 	 	 	 	 	 
	 

	 	Dated:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Holder’s Signature:	 	 	 	 
	 

	 	 	 	 	 	 

	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Holder’s Address:	 	 	 	 
	 

	 	 	 	 	 	 

	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 

 13.EX-10.22

 

EXHIBIT 10(22)

WAIVER AND CONSENT

     This WAIVER AND CONSENT (this “Agreement”) is made and entered into as of the 28th
day of June, 2006 by and among CanArgo Energy Corporation, a Delaware corporation (the “Company”),
and the individuals and entities who or which are signatories hereto (hereby referred to as a
“Senior Noteholder” and collectively as the “Senior Noteholders”).

     WHEREAS, the Company and certain individuals propose to enter into a Note and Warrant Purchase
Agreement (the “Note and Warrant Purchase Agreement”) pursuant to which the Company shall issue up
to $10,000,000 in convertible promissory notes (the “12% Subordinated Notes”) on the Closing Date
(as defined in the Note and Warrant Purchase Agreement) and warrants to purchase up to 12.5 million
shares, at an exercise price of $1.00 per share, subject to adjustment, of the Company’s common
stock, par value $.10 per share, on the Closing Date, expiring on the second anniversary of the
Closing Date (the “Warrants,” and together with the 12% Subordinated Notes, the “12% Subordinated
Offering”) thereafter and in accordance with the terms thereof; and

     WHEREAS, the principal amount of each 12% Subordinated Note shall be from time to time in
whole or in part convertible at the option of the holder thereof into shares of the Company’s
common stock at a price per share equal to $1.00 per share, as such price may be adjusted pursuant
to the terms of the Note and Warrant Purchase Agreement; and

     WHEREAS, the Senior Noteholders have certain rights (the “Senior Noteholder Rights”) under
that Note Purchase Agreement dated July 25, 2005 by and among the Company and the Senior
Noteholders signatory thereto (the “Senior Note Purchase Agreement”) and the ancillary documents
associated therewith relating to the issue of the Company’s Senior Secured Notes due July 25, 2009
(“Senior Secured Notes”), which rights may include, without limitation, (i) anti-dilution rights
and protections, and preemptive and notice rights with respect to certain issuances of securities
by the Company, (ii) rights in connection with negative covenants provided by the Company in
Section 11 of the Senior Note Purchase Agreement and (ii) other rights as described therein; and

     WHEREAS, Ingalls & Snyder Value Partners L.P., as the holder of $14 million in aggregate
outstanding principal amount of the Senior Secured Notes, constitutes a “Required Holder” as
defined in the Senior Note Purchase Agreement and is a proper party to waive certain of the Senior
Noteholder Rights that the Senior Noteholders may have in connection with the Note and Warrant
Purchase Agreement and the transactions contemplated thereby and to amend certain provisions of the
Senior Note Purchase Agreement;

     NOW, THEREFORE, in consideration of the foregoing and for other good and valuable
consideration, the receipt and sufficiency or which is hereby acknowledged, the parties hereto,
intending to be legally bound, hereby agree as follows:

     1. Definitions.

	 	a.	 	As used in this Agreement, the following term shall have the
following meaning ascribed thereto: “Tethys Spin Out” means an offering of
Tethys Common Stock with aggregate gross proceeds to Tethys of not less than
$18 million and may include in connection therewith the sale of shares of
Tethys Common Stock by the Company in such offering in which case the Company
at its sole discretion shall be entitled to sell in such offering up to such
number of shares of Tethys Common Stock as would take its equity interest in
Tethys to below 50% of the total issued share capital of Tethys, provided
however, that (a) the offering values Tethys on a pre-money basis at a
minimum of $52 million; and (b) at least 50% of the net proceeds received by
the company following any sale of its shares of Tethys Common Stock are

55

 

	 	 	 	immediately upon receipt of such proceeds by the Company used to make a
prepayment in respect of the Senior Secured Notes.
	 	b.	 	Capitalized terms used herein but not otherwise defined have
the meanings assigned to them in the Senior Note Purchase Agreement.

     2. Consent and Waivers. Notwithstanding the provisions of any Loan Document, in
accordance with Section 18 of the Senior Note Purchase Agreement the Senior Noteholders hereby
irrevocably and unconditionally consent to, and waive any rights they may have under the Senior
Note Purchase Agreement or any other Loan Documents in connection with: (i) the 12% Subordinated
Offering, including, without limitation, (w) the terms of the Note and Warrant Purchase Agreement,
(x) the sale and issuance of the 12% Subordinated Notes and the Warrants pursuant to the terms and
provisions of the Note and Warrant Purchase Agreement, (y) the application of any of the negative
covenants set forth in Section 11 of the Senior Note Purchase Agreement to the 12% Subordinated
Offering and (z) the Subordinated Subsidiary Guaranty (as defined in the Note and Warrant Purchase
Agreement) to be entered into in connection with the 12% Subordinated Offering, and (ii) the Tethys
Spin Out, including, without limitation (x) the application of the negative covenants set forth in
Section 11 of the Senior Note Purchase Agreement; and (y) the release of Tethys and Tethys
Kazakhstan Limited as Subsidiary Guarantors under the Subsidiary Guaranty. The waivers granted in
this Section 2 only apply to the matters described in clause (i) and (ii) above, and do not
constitute any consent to any other action or a waiver of any other provisions of the Loan
Documents.

     3. Purchase Option. In consideration of $1.00 and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged and confirmed Ingalls &
Snyder Value Partners L.P. hereby grants the holders of the 12% Subordinated Notes (the
“Subordinated Noteholders”) an irrevocable option to purchase all of its Senior Secured Notes at a
purchase price equal to the outstanding principal amount thereof together with any accrued but
unpaid interest thereon to the date of sale thereof payable in immediately available United States
dollars exercisable solely upon the occurrence of an event of Default under the Senior Secured
Notes and any resultant acceleration of the Senior Secured Notes pursuant to Section 13 of the
Senior Note Purchase Agreement and; provided, further, that in connection with the exercise of this
option, the Subordinated Noteholders shall irrevocably offer to purchase the remaining outstanding
Senior Secured Notes upon the same terms and conditions as the purchase from Ingalls & Snyder Value
Partners L.P. Ingalls & Synder LLC shall use its commercially reasonable efforts (but without the
necessity of making any payments) to assist the Subordinated Noteholders in consummating their
offer to purchase the remaining outstanding Senior Secured Notes.

a. Option Exercise. Concurrently with the delivery of notice of acceleration of the
Senior Secured Notes to the Company (or, in the case of an acceleration without prior
required notification, upon the occurrence of the event triggering such acceleration), the
Company shall give written notice to the Subordinated Noteholders with a copy to the
holders of the Senior Noteholders (the “Company’s Notice”), referring to Section 3
of this Waiver and Consent; conveying the offer of the Subordinated Noteholders to purchase
the remaining outstanding Senior Secured Notes on the same terms and conditions as the
purchase of the Senior Secured Notes held by Ingalls & Snyder Value Partners L.P.;
specifying that the closing of the purchase and sale of the Senior Secured Notes shall
occur at the offices of Satterlee Stephens Burke & Burke LLP, 230 Park Avenue, Suite 1130,
New York, NY at 10:00 am local time on the twentieth (20th) Business Day after the date of
the Company’s Notice or at such other place, date and time as the Agent and the
Subordinated Noteholders may mutually agree (the “Closing”); specifying the
purchase price to be paid for the Senior Secured Notes (the “Purchase Price”) in
cash in immediately available funds wire transferred for deposit to an account identified
in the Company’s Notice, and identifying the payees. The Subordinated Noteholders shall
have a period of fifteen (15) Business Days from the date of the Company’s Notice to elect
to exercise their option in whole only and to make their irrevocable offer to purchase the
remaining Senior Secured Notes by delivering a written notice of exercise and offer to the
Company with a copy to the Agent (the “Exercise Notice”). The delivery of the
Exercise Notice shall constitute an irrevocable commitment to purchase such Senior Secured
Notes for the Purchase Price at the Closing. Such Notice shall

56

 

identify the purchasers of the Senior Secured Notes and shall allocate and specify the
Senior Secured Notes which shall be purchased by the individual Subordinated Noteholders.
At the Closing original copies of the Senior Secured Notes shall be delivered to the
Subordinated Noteholders or their duly authorized agent in a form transferable by delivery
free and clear of all liens, charges and encumbrances arising by, through or under the
Senior Noteholders.

     4. Effect on Loan Documents. This Agreement is limited to the specific purpose for
which it is granted and, except as specifically set forth above, (a) shall not be construed as a
consent, waiver or other modification with respect to any term, condition or other provision of any
Loan Document and (b) each of the Loan Documents shall remain in full force and effect and are each
hereby ratified and confirmed.

     5. Miscellaneous.

     (a) Successors and Assigns. This Agreement shall be binding on and shall inure to the
benefit of the Company and the Senior Noteholders (and with respect to the provisions of Section 3
hereof the Subordinated Noteholders) and their respective successors and assigns; provided that the
Company may not assign its rights hereunder without the prior written consent of the Required
Holders. Except to the extent set forth in Section 3 hereof, there shall be no third party
beneficiaries of any of the terms and provisions of this Agreement.

     (b) Entire Agreement. This Agreement, including all documents attached hereto,
incorporated by reference herein or delivered in connection herewith, constitutes the entire
agreement of the parties with respect to the subject matter hereof and supersedes all other
understandings, oral or written, with respect to the subject matter hereof.

     (c) Severability. Whenever possible each provision of this Agreement shall be
interpreted in such manner as to be effective and valid under applicable law, but if any provision
of this Agreement shall be prohibited by or invalid under such law, such provision shall be
ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of
such provision or the remaining provisions of this Agreement.

     (d) Counterparts.
This Agreement may be executed in any number of counterparts
and by the different parties on separate counterparts, and each such counterpart shall be deemed to
be an original, but all such counterparts shall together constitute but one and the same
instrument. Delivery of an executed counterpart of a signature page to this Agreement by telecopy
shall be effective as delivery of a manually executed counterpart of this Agreement.

57

 

     IN WITNESS WHEREOF, this Waiver Agreement has been executed by the parties hereto or by their
representatives, thereunto duly authorized, as of the day and year first above written.

	 	 	 	 	 	 	 	 	 
	 	 	CANARGO ENERGY CORPORATION	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	By:	 	/s/ Dr. David Robson	 	 
	 
	 	 	 	Name:	 	Dr. David Robson	 
	 	 
	 
	 	 	 	Title:
	 	Chairman and Chief Executive Officer	 
	 	 
	 
	 	 	 	 	 	 
	 	 

SENIOR NOTEHOLDERS:

INGALLS & SNYDER VALUE PARTNERS L.P.

As a Senior Noteholder and in its capacity as the

“Required Holder”

	 	 	 	 	 
	By:
	 	/s/ Thomas Boucher 	 	 
	Name:

	 	Thomas O. Boucher Jr 
	 	 
	Title:

	 	General Partner 
	 	 
	 

	 	 
	 	 

58

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]